• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MedAlliance enrolls first patient in study of drug-eluting balloon for treating erectile dysfunction

September 9, 2022 By Sean Whooley

MedAlliance SELUTION SLRMedAlliance announced today that it enrolled the first patient in a trial for its drug-eluting ballon in treating erectile dysfunction.

Geneva, Switzerland-based MedAlliance said an 82-year-old Taiwanese man enrolled in the initial trial. It will evaluate the Selution SLR sirolimus-eluting balloon for the treatment of erectile dysfunction (ED).

The Perfect-Selution FIM study includes 54 patients. The participants suffer from distal internal pudendal-penile artery stenotic disease and ED. They are being randomized to either Selution SLR treatment or plain old balloon angioplasty. There will be a follow-up period of 12 weeks.

MedAlliance said the primary efficacy endpoint is angiographic binary restenosis defined by CT. The primary safety endpoint is the rate of major adverse events.

“We are excited to begin this study on such a long-suffering patient population. We hope that this study will give these patients a better chance of a normal life, and look forward to the results,” said Tzung-Dau Wang, professor of medicine and director of Cardiac Cath Lab, National Taiwan University Hospital. “We do need state-of-the-art technology to break this barrier. We are pleased to initiate this study: the first patient has responded well to this therapy.”

The study comes on the heels of a feasibility study conducted in Europe last year. That study involved 10 patients with ED.

“We have been very pleased with the clinical results of this technology in many applications: in-stent restenosis, coronary de novo, both below and above the knee, AV fistula and now erectile dysfunction,” MedAlliance Chair and CEO Jeffrey B. Jump said. “This combination drug-device technology seems to be very versatile, and we look forward to the results from this physician-initiated study, as this is clearly an unmet need touching the lives of hundreds of millions of people.”

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: MedAlliance

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS